Evidence map›Paper›PMID 40813592›Full record

ArticleNature communications2025

A broadly neutralizing antibody recognizes a unique epitope with a signature motif common across coronaviruses.

Lei Yan, Fulian Wang, Michelle Hill, Juliane Brun, Ze Liang, Xinyu Shi, Liangminghui Zhang, Xiuxiu He, Yu Li, Qianping Huang and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Lei YanShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China.ORCID http://orcid.org/0000-0003-1775-5533
Fulian WangShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China.
Michelle HillJames & Lillian Martin Centre, Sir William Dunn School of Pathology, University of Oxford, Oxford, UK.
Juliane BrunDepartment of Biochemistry, Oxford Glycobiology Institute, Oxford, UK.
Ze LiangInternational Research Center of Synthetic Biology, School of Food Science and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, China.
Xinyu ShiInternational Research Center of Synthetic Biology, School of Food Science and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, China.
Liangminghui ZhangInternational Research Center of Synthetic Biology, School of Food Science and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, China.
Xiuxiu HeInternational Research Center of Synthetic Biology, School of Food Science and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, China.
Yu LiShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China.
Qianping HuangShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China.
Xuxue DongShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China.
Huanzhen LiuShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China.
Yi ZhangShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China.
Lili LiuShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China.
Raymond A DwekDepartment of Biochemistry, Oxford Glycobiology Institute, Oxford, UK.ORCID http://orcid.org/0000-0001-9989-2245
Nicole ZitzmannDepartment of Biochemistry, Oxford Glycobiology Institute, Oxford, UK.ORCID http://orcid.org/0000-0003-1969-4949
Aibin LiangDepartment of Hematology, Tongji Hospital, Tongji University School of Medicine, Shanghai, China. lab7182@tongji.edu.cn.ORCID http://orcid.org/0000-0002-8978-1987
Guang YangShanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China. yangguang@shanghaitech.edu.cn.ORCID http://orcid.org/0000-0001-7379-6810

Funding

Jiangsu Science and Technology Department BK20233003Ministry of Science and Technology of the People's Republic of China (Chinese Ministry of Science and Technology) 2021YFA1100800
6 · The paper itself

Abstract

Cross-reactive antibodies targeting multiple epitopes have been identified in Sarbecoviruses, but the precise molecular mechanism(s) behind the crossreactivity remain poorly understood. Here, we isolate 3D1, a broadly neutralizing antibody (bnAb) derived from a human combinatorial antibody library targeting the conserved HR1 domain. 3D1 uniquely recognizes a β-turn fold comprising a 6-mer peptide (pep

Indexed as

Antibodies, NeutralizingAntibodies, ViralBroadly Neutralizing AntibodiesCoronavirusEpitopesSARS-CoV-2Amino Acid MotifsAnimalsCOVID-19Cross ReactionsHumansNeutralization TestsSpike Glycoprotein, CoronavirusAntibodies, NeutralizingAntibodies, ViralBroadly Neutralizing AntibodiesEpitopesSpike Glycoprotein, Coronavirus

Identifiers

PMID40813592
PMCPMC12354777

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.